Antimony Susceptible : Evidence from Drug Susceptibility of Parasites Isolated from Patients of Post-kala-azar Dermal Leishmaniasis in Pre- and Post-miltefosine Era

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 May 7

PMID 38712926

Authors

Sushmita Ghosh

Aditya Verma

Dhiraj Kumar

Deepak Kumar Deep

V Ramesh

Poonam Salotra

Ruchi Singh

Affiliations

Soon will be listed here.

Abstract

Importance: Post-kala-azar dermal leishmaniasis (PKDL) patients, a key source of parasites, hinder eliminating visceral-leishmaniasis. Assessment of the susceptibility of PKDL isolates to antimony, miltefosine (MIL), and amphotericin-B indicated that recent isolates remain susceptible to antimony, enabling its use with other drugs for treating PKDL.

References

Thakur C, Narayan S, Ranjan A . Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res. 2004; 120(3):166-72. View

Datta A, Podder I, Das A, Sil A, Das N . Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options. Indian J Dermatol. 2021; 66(1):34-43. PMC: 8061474. DOI: 10.4103/ijd.IJD_264_20. View

Bhandari V, Kulshrestha A, Deep D, Stark O, Prajapati V, Ramesh V . Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis. 2012; 6(5):e1657. PMC: 3358331. DOI: 10.1371/journal.pntd.0001657. View

Kumar D, Kulshrestha A, Singh R, Salotra P . In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother. 2008; 53(2):835-8. PMC: 2630609. DOI: 10.1128/AAC.01233-08. View

Sundar S, Singh J, Dinkar A, Agrawal N . Safety and Effectiveness of Miltefosine in Post-Kala-Azar Dermal Leishmaniasis: An Observational Study. Open Forum Infect Dis. 2023; 10(5):ofad231. PMC: 10205550. DOI: 10.1093/ofid/ofad231. View

Ramesh V, Singh R, Avishek K, Verma A, Deep D, Verma S . Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. PLoS Negl Trop Dis. 2015; 9(10):e0004093. PMC: 4619646. DOI: 10.1371/journal.pntd.0004093. View

Desjeux P, Ghosh R, Dhalaria P, Strub-Wourgaft N, Zijlstra E . Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012. Parasit Vectors. 2013; 6:196. PMC: 3733610. DOI: 10.1186/1756-3305-6-196. View

Zijlstra E, Musa A, Khalil E, el-Hassan I, El-Hassan A . Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003; 3(2):87-98. DOI: 10.1016/s1473-3099(03)00517-6. View

Das V, Pandey R, Siddiqui N, Chapman L, Kumar V, Pandey K . Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS Negl Trop Dis. 2016; 10(12):e0005196. PMC: 5156552. DOI: 10.1371/journal.pntd.0005196. View

10.

Srivastava S, Mishra J, Gupta A, Singh A, Shankar P, Singh S . Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Parasit Vectors. 2017; 10(1):49. PMC: 5282768. DOI: 10.1186/s13071-017-1969-z. View

11.

Pandey K, Pal B, Siddiqui N, Lal C, Ali V, Bimal S . A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis. Indian J Dermatol Venereol Leprol. 2021; 87(1):34-41. DOI: 10.25259/IJDVL_410_19. View

12.

Le Rutte E, Zijlstra E, de Vlas S . Post-Kala-Azar Dermal Leishmaniasis as a Reservoir for Visceral Leishmaniasis Transmission. Trends Parasitol. 2019; 35(8):590-592. PMC: 6667731. DOI: 10.1016/j.pt.2019.06.007. View

13.

Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L . Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res. 2012; 112(2):825-8. DOI: 10.1007/s00436-012-3212-3. View

14.

Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S . Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis. 2012; 206(5):752-5. PMC: 4125624. DOI: 10.1093/infdis/jis424. View

15.

Mandal S, Maharjan M, Singh S, Chatterjee M, Madhubala R . Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother. 2010; 65(3):496-507. DOI: 10.1093/jac/dkp468. View

16.

Marquis N, Gourbal B, Rosen B, Mukhopadhyay R, Ouellette M . Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol. 2005; 57(6):1690-9. DOI: 10.1111/j.1365-2958.2005.04782.x. View

17.

Downing T, Imamura H, Decuypere S, Clark T, Coombs G, Cotton J . Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011; 21(12):2143-56. PMC: 3227103. DOI: 10.1101/gr.123430.111. View

18.

Perez-Victoria F, Sanchez-Canete M, Seifert K, Croft S, Sundar S, Castanys S . Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat. 2006; 9(1-2):26-39. DOI: 10.1016/j.drup.2006.04.001. View

19.

Ramesh V, Kaushal H, Mishra A, Singh R, Salotra P . Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. BMC Public Health. 2015; 15:1092. PMC: 4621871. DOI: 10.1186/s12889-015-2424-8. View

20.

Singh R, Kumar D, Ramesh V, Negi N, Singh S, Salotra P . Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis. 2006; 194(3):302-6. DOI: 10.1086/505079. View